Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Thoracic Neoplasms 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

Pemetrexed 4pembrolizumab 3Ramucirumab 2Gemcitabine 2Carboplatin 2vistusertib 1vandetanib 1tusamitamab ravtansine 1telomerase reverse transcriptase p572Y, human 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1Vinorelbine 1LY3023414 1Injections 1Immune Checkpoint Inhibitors 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Cisplatin 1Bevacizumab 1AZD4547 1AZD 8931 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-small Cell Lung Cancer Metastatic × necitumumab × Clear all
NCT02443337 2020-12-09

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Eli Lilly and Company

Phase 2 Terminated
31 enrolled 14 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡